Novartis’ Phase 3 cholesterol study fails key cardiovascular goal
Novartis said a highly anticipated cholesterol drug failed in a Phase 3 study to reduce the risk of severe cardiovascular outcomes, according to reporting by WSJ.
By Lizzy Lawrence and Xavier Martinez Novartis said its highly anticipated cholesterol drug did not reduce the risk of severe cardiovascular outcomes in a Phase 3 study, marking a setback for the company and other groups pursuing a new approach to preventing cardiovascular disease. The company said that the drug…